A longitudinal analysis of blood samples from patients with advanced NSCLC undergoing PD-1 therapy revealed that approximately 70% of the patients exhibited an increased proportion of Ki67+PD-1+CD8+ T cells after the initial or second treatment cycle (32). This evidence concerns the gene CD8A and non-small cell lung carcinoma.